Clinical Trial Update: Pamiparib in mCRPC With HRD or BRCA1/2 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial update for pamiparib in metastatic castration-resistant prostate cancer with HRD or BRCA1/2 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pamiparib (pamiparib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN